"MART-1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.
| Descriptor ID |
D058965
|
| MeSH Number(s) |
D12.776.624.301.750 D23.050.285.439.750
|
| Concept/Terms |
MART-1 Antigen- MART-1 Antigen
- Antigen, MART-1
- MART 1 Antigen
- MART1 Antigens
- Antigens, MART1
- MelanA
- Melanoma Antigen Recognized by T-Cells 1
- Melanoma Antigen Recognized by T Cells 1
- MART1 Antigen
- Antigen, MART1
- Melan-A
- Melan A
|
Below are MeSH descriptors whose meaning is more general than "MART-1 Antigen".
Below are MeSH descriptors whose meaning is more specific than "MART-1 Antigen".
This graph shows the total number of publications written about "MART-1 Antigen" by people in this website by year, and whether "MART-1 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 4 | 4 |
| 1998 | 0 | 4 | 4 |
| 1999 | 0 | 4 | 4 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 7 | 7 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 6 | 6 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "MART-1 Antigen" by people in Profiles.
-
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
-
Diagnostic utility of SOX10 immunostaining in benign lichenoid keratosis: A study of 21 cases. J Cutan Pathol. 2023 Jan; 50(1):51-55.
-
Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer. 2021 05; 9(5).
-
Three Types of Nodal Melanocytic Nevi in Sentinel Lymph Nodes of Patients With Melanoma: Pitfalls, Immunohistochemistry, and a Review of the Literature. Am J Dermatopathol. 2020 Oct; 42(10):739-744.
-
Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses. J Exp Med. 2020 07 06; 217(7).
-
Epithelioid angiomyolipoma mimicking metastatic melanoma in a liver tumor. J Cutan Pathol. 2020 Sep; 47(9):824-828.
-
SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity. Cancer Immunol Res. 2017 08; 5(8):618-629.
-
Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice. Oncotarget. 2016 Feb 09; 7(6):6448-59.
-
Atypical histopathologic features in a melanocytic nevus after cryotherapy and pregnancy. J Cutan Pathol. 2014 Oct; 41(10):802-5.
-
Reliability of immunostaining using pan-melanoma cocktail, SOX10, and microphthalmia transcription factor in confirming a diagnosis of melanoma on fine-needle aspiration smears. Cancer Cytopathol. 2014 Oct; 122(10):779-85.